Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Capecitabine
Drug ID BADD_D00349
Description Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Indications and Usage For the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen. May also be used in combination with docetaxel for the treatment of metastatic breast cancer in patients who have failed to respond to, or recurred or relasped during or following anthracycline-containing chemotherapy. Capecitabine is used alone as an adjuvant therapy following the complete resection of primary tumor in patients with stage III colon cancer when monotherapy with fluroprymidine is preferred. The use or capecitabine in combination regimens for advanced gastric cancer is currently being investigated.
Marketing Status Prescription
ATC Code L01BC06
DrugBank ID DB01101
KEGG ID D01223
MeSH ID D000069287
PubChem ID 60953
TTD Drug ID D00HCQ
NDC Product Code 72205-007; 69097-948; 59923-722; 59651-204; 0378-2511; 55111-893; 55111-496; 0054-0272; 72205-006; 70756-816; 50268-154; 51407-095; 15308-0714; 16714-467; 62756-239; 67877-458; 64980-277; 55512-0015; 16729-072; 68001-487; 67877-459; 55111-497; 51079-510; 35369-0010; 54893-0002; 70756-815; 63482-099; 60687-149; 0004-1101; 62331-043; 72485-205; 53183-4009; 69539-019; 0004-1100; 65162-843; 16729-073; 72969-094; 62756-238; 16714-468; 68554-0033; 69097-949; 54245-7014; 72485-204; 62756-088; 0054-0271; 59651-205; 0093-7473; 72606-555; 76302-001; 69539-020; 65162-844; 53104-7618; 0378-2512; 51407-096; 81955-0001; 63759-0001; 49452-1713; 68001-488; 65129-1241; 64980-276; 0093-7474; 72606-554; 59923-721
Synonyms Capecitabine | N(4)-pentyloxycarbonyl-5'-deoxy-5-fluorocytidine | Xeloda
Chemical Information
Molecular Formula C15H22FN3O6
CAS Registry Number 154361-50-9
SMILES CCCCCOC(=O)NC1=NC(=O)N(C=C1F)C2C(C(C(O2)C)O)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Angina pectoris02.02.02.002; 24.04.04.0020.006127%
Angina unstable02.02.02.004; 24.04.04.004--Not Available
Angioedema10.01.05.009; 23.04.01.001--Not Available
Ankle fracture12.04.01.005; 15.08.03.005--
Anorectal disorder07.03.01.001--Not Available
Anterior spinal artery syndrome17.10.01.008; 24.04.06.0150.000799%Not Available
Anuria20.01.03.0020.000486%Not Available
Anxiety19.06.02.002--
Aphasia17.02.03.001; 19.21.01.001--
Aplasia03.02.01.002; 08.03.04.0030.000533%Not Available
Arrhythmia02.03.02.0010.006127%Not Available
Arrhythmia supraventricular02.03.03.001--Not Available
Arteriospasm coronary02.02.02.005; 24.04.04.0050.019182%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Ascites02.05.04.002; 07.07.01.001; 09.01.05.0030.005595%
Aspartate aminotransferase abnormal13.03.01.0040.000799%Not Available
Aspartate aminotransferase increased13.03.01.006--
Aspiration22.02.07.0070.000417%
Asthenia08.01.01.0010.038896%Not Available
Asthma10.01.03.010; 22.03.01.002--Not Available
Ataxia08.01.02.004; 17.02.02.001--
Atrial fibrillation02.03.03.002--
Atrioventricular block02.03.01.002--Not Available
Azotaemia20.01.01.0010.000799%Not Available
Back pain15.03.04.005--
Bacteraemia11.01.11.0010.001865%
Balanoposthitis21.09.03.001--Not Available
Biliary colic09.02.01.0010.000533%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 35 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene